GSK573719 IV Enabling Study

NCT01110018 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK573719 (SOLUTION)
DRUG: GSK573719 (INHALATION POWDER)

Sponsor

GlaxoSmithKline